Nomura Holdings’s Tvardi Therapeutics TVRD Stock Holding History

Nomura Holdings’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2,778	Closed	-$1.54M	–	1651
2017 Q2	$1.54M	Buy	+2,778	New	+$1.76M	﹤0.01%	917

Other funds holding TVRD

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCP

Rho Capital Partners New York $20.4M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nomura Holdings's TVRD Position: Q3 2017 in Review

Nomura Holdings sold out of Tvardi Therapeutics (TVRD) in Q3 2017, closing a stake of 2,778 shares — an estimated $1.54M sold.

Nomura Holdings first reported a position in TVRD in Q2 2017 and held it in 1 quarter. The position peaked at $1.54M in Q2 2017. 121 funds tracked by Wall St. Rank hold TVRD as of Q3 2017.

Nomura Holdings reported no remaining Tvardi Therapeutics position as of Q3 2017 after selling out during the quarter.
Nomura Holdings sold 2,778 Tvardi Therapeutics shares in Q3 2017, an estimated $1.54M.
Nomura Holdings first reported a position in Tvardi Therapeutics in Q2 2017 and held it in 1 quarter.
Nomura Holdings's Tvardi Therapeutics position peaked at $1.54M in Q2 2017.
121 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2017.

Based on Nomura Holdings's 13F filing for Q3 2017, filed 14 Nov 2017.